Studier på Xanthigen™ komplex

50 % granat-epleekstrakt og 50 % brunalgeekstrakt

De aktive ingrediensene i Xanthigen™komplex består av 50 % granat-epleekstrakt (Punica Granatum) og 50 % brunalgeekstrakt (Undaria Pinnafitida). Det er gjennomført flere kliniske studier på effekten av Xanthigen™ komplex.

Synergieffekt
De aktive ingrediensene i Xanthigen™komplex viste seg i en studie å ha synergieffekt. Sammen gir de nesten dobbel så stor effekt, enn når de blir inntatt hver for seg.

Klinisk studie
I en klinisk studie på Xanthigen som gikk over 16 uker, deltok 151 overvektige kvinner. Alle fikk samme diett (1 800 kcal/døgn) og alle gikk ned i vekt. Dietten besto 50 % karbohydrater, 30 % protein og 20 % fett. Mens placebogruppen hadde et gjennomsnittlig vekttap på 1,4 kg, hadde gruppen som fikk Xanthigen et gjennomsnittlig vekttap på 6,4 kg. Studiet viste at Xanthigen økte vekttapet ved et lavere kalorinntak enn normalt.

Du finner et sammendrag av dette studiet under. Studiet foreligger også som nedlastbar PDF-fil.


Diabetes, Obesity and Metabolism 12: 72–81, 2010.

The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat

Abidov MRamazanov ZSeifulla RGrachev S.

Institute of Immunopathology, Russian Academy of Natural Sciences, Moscow, Russia.

Abstract

AIM: To investigate the effects of Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil (PSO)) on body weight, body fat, liver lipids, and blood biochemistry; and Xanthigen and its individual components on resting energy expenditure (REE) in obese, non-diabetic female volunteers with non-alcoholic fatty liver disease (NAFLD) and normal liver fat (NLF) content.

METHODS: Sixteen-week, double-blind, randomized, placebo-controlled study. Food record data, body composition, REE (only 41 volunteers with NAFLD) and blood sample analysis were assessed weekly for 16 weeks in 151 non-diabetic, obese premenopausal women with liver fat content above 11% (NAFLD) n = 113, and below 6.5% (NLF) n = 38.

RESULTS: Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight (5.5 +/- 1.4 kg NAFLD group and 4.9 +/- 1.2 kg NLF group, p < 0.05), waist circumference (NAFLD group only), body (3.5 +/- 1.9 kg NAFLD group, p < 0.001; 3.6 +/- 0.7 kg NLF group, p < 0.05) and liver fat content, liver enzymes (NAFLD group only), serum triglycerides and C-reactive protein. Weight loss and reduction in body and liver fat content occurred earlier in patients with NLF than in patients with NAFLD. Fucoxanthin (> 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased REE in NAFLD subjects compared to placebo.

CONCLUSIONS: Xanthigen promoted weight loss, reduced body and liver fat content, and improved liver function tests in obese non-diabetic women. Xanthigen and Fucoxanthin also increased REE. This product may be considered a promising food supplement in the management of obesity.

Share